| External factors: | T-oligo |
| Aging type: | Accelerate |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Colorectal cancer |
| Experiment: | SA-β-gal activity assay//Cell morphological analysis |
| Description: | 44.8% of cells treated with T-oligo were senescence associated β-galactosidase (SA β-gal) positive compared to only 3.9% and 4.5% of cells treated with diluent and C-oligo, respectively. T-oligo-treated cells were also larger in size, which is characteristic of cells undergoing senescence. T-oligo increased expression of senescent markers p53 (2.0-fold), p27 (1.8-fold), and p21 (2.0-fold). |
| Target gene: | POT1//TRF2 |
| R-EF-Target gene: | Downregulation//Downregulation |
| Official symbol(s): | POT1//TERF2 |
| Target gene experiment: | Western blot//Immunfluorescence |
| Target gene description: | We demonstrated that T-oligo treatment downregulated TRF2 in LoVo (2.4-fold, p<0.01) and HT-29 (1.8-fold (p<0.02) cells compared to C-oligo treatment as assessed by immunfluorescence. Additionally, T-oligo treatment downregulates POT1 in both HT-29 (2-fold) and LoVo (3-fold) cells at 48 h and 72 h, respectively as seen by immunoblotting. |
| Regulatory pathway: | -- |
| R-EF-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation: